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Background
Malignant hyperthermia (MH) is a complication of
anaesthesia appearing as an acute potentially lethal
hypermetabolic state in people carrying a genetic anom-
aly expressed in the skeletal muscle. Clinical guidelines
aim to help health professionals and patients make the
best decisions about treatment or care for a particular
condition or situation. The guidelines are typically writ-
ten in statement form by a reputable organization. The
authors of guidelines review the research literature and
take advice from experts to gather the current evidence
on which to base the recommendations in a guideline.
Doctors, nurses and other health care professionals are
encouraged to follow clinical guidelines where appropri-
ate [http://www.patient.co.uk/guidelines.asp].
The French Society of Anesthesiology and Intensive
Care (SFAR) decided in 2012 to ask the French MH
Group (FMHG) to write Guidelines for the management
of Malignant Hyperthermia. The FMHG gathers the
professionals in charge of the Five MH Centers involved
in the diagnosis of MH by performing in vitro contrac-
ture test (IVCT), genetic analysis and/or an expert
advice. Pr Renée Krivosic-Horber, Dr. Anne-Frédérique
Dalmas Centre HM Lille, Pr Yves Nivoche Centre HM
Robert Debré Paris, Pr Jean-François Payen Chu Greno-
ble, Pr Joël Lunardi, Madame Nicole Monnier, Pr Julien
Faure Centre de Biologie Moléculaire CHU de Grenoble,
Dr Alexandre Moerman Génétique Clinique CHRU de
Lille, Dr Thierry Girard MH Center Basel Suisse was
asked to give his opinion as a french speaking interna-
tional expert.
Three meetings and many exchanges by mail between
the experts and with the colleagues in charge of the Guide-
lines Board of the SFAR were necessary to obtain a consen-
sus from all the participants. Eventually the text was




Dr. Krivosic-Horber has been invited to present the
Guidelines with a written paper in the annals, at the
annual meeting of the SFAR in Paris in September 2014.
Index of the Guidelines:
1) Screening of the risk of MH susceptibility during
the “consultation d’anesthesie” (which is legally man-
datory in France).
2) How to do the diagnosis of MH susceptibility
(IVCT or Genetic?)
3) How to perform an anesthesia free of MH risk.
4) Management of the MH crisis: presented as a pos-
ter with diagnosis and treatment on one side and
stock and preparation of dantrolene on the other side.
5) What to do after the crisis.
6) The addresses of the MH centers and a map
showing the type of diagnosis they can provide.
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